Panzyga (human immune globulin intravenous 10% stabilised with glycine) / Octapharma  >>  Phase 4
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Panzyga (human immune globulin intravenous 10% stabilised with glycine) / Octapharma
NCT03866798 / 2019-004063-49: Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP)

Active, not recruiting
4
20
US
Panzyga
Octapharma
Chronic Immune Thrombocytopenia
04/24
04/24

Download Options